The pharmaceutical industry has entered a new chapter in the obesity treatment race as Eli Lilly officially launched Foundayo (orforglipron), its first oral GLP-1 medication. This move follows the drug’s FDA approval on April 1, 2026, marking Lilly’s push to challenge Novo Nordisk’s first-mover advantage in the oral weight-loss segment.
Key product differentiators:
-
Dosing Convenience: Lilly is positioning Foundayo as a more flexible option that can be taken at any time of day, regardless of food or water intake. In contrast, the oral version of Wegovy—which launched three months earlier—must be taken on an empty stomach in the morning, followed by a 30-minute fasting period.
-
Clinical Efficacy: Current trial data gives the Wegovy pill a slight edge in weight reduction (approximately 16.6%) compared to Foundayo (approximately 12.4%). However, Foundayo’s non-peptide, small-molecule structure offers a manufacturing advantage, potentially allowing for more efficient large-scale production.
-
Pricing Strategy: Both companies have anchored their entry-level monthly pricing at $149 for self-pay patients. With savings cards and expanded insurance coverage, some patients may pay as little as $25 per month, while eligible Medicare beneficiaries could see costs around $50 starting July 2026.
The transition from injectables to oral tablets is expected to significantly broaden the patient base, particularly for those initiating GLP-1 therapy for the first time. Analysts project Foundayo could generate up to $1.6 billion in its debut year, working alongside the injectable Zepbound to strengthen Lilly’s dominant position in the metabolic health market.